Catalyst Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Catalyst Pharmaceuticals's estimated annual revenue is currently $17.3M per year.
- Catalyst Pharmaceuticals's estimated revenue per employee is $201,000
- Catalyst Pharmaceuticals has 86 Employees.
- Catalyst Pharmaceuticals grew their employee count by 12% last year.
Catalyst Pharmaceuticals Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for FirdapseÂ® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was recently approved by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA. Firdapse is currently being evaluated in clinical trials for the treatment of CMS, MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.keywords:N/A
Number of Employees
Employee Growth %
Catalyst Pharmaceuticals News
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel...
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with...
Shares of Catalyst Pharmaceuticals Inc. CPRX, -2.72% slipped 2.72% to $8.24 Thursday, on what proved to be an all-around dismal trading...
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)'s share price reached a new 52-week high on Friday . The stock traded as high as $6.69 and ...
Intraday Trading of Catalyst Pharmaceuticals, Inc.: If one intends to pursue a career as a trader, then one must understand and choose between ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|